ImQuest BioSciences strives to provide research and development services to the highest scientific standards and expects that data provided by the laboratories will be suitable for publication in peer reviewed journals, in Investigational New Drug applications with the FDA, as components of due diligence resulting in licensing opportunities, and as presentations at international meetings and workshops. The greatest source of pride for ImQuest is the acceptance of manuscripts, the funding of grants and contracts and the acceptance of INDs and meeting presentations because these submissions are reviewed by our scientific peers and judged worthy. Please take a moment and share some of ImQuest's recent successes.
Elusys Therapeutics is a privately-held biopharmaceutical company focused on the development of antibody-based therapies for the treatment of infectious disease. The Company has pioneered the development of a rapid injection, therapeutic antibody, AnthimÔ, for the treatment of anthrax infection following a biowarfare attack. Anthim has completed a phase I safety study and is a leading candidate for purchase by the US government. Elusys' Heteropolymer (HP) Antibody technology targeting complement receptors has demonstrated a unique ability to clear and destroy pathogens and provides a platform to develop a broad pipeline of novel drug candidates targeted against bacterial, viral and fungal infections. ETI-211, a preclinical candidate for the treatment of antibiotic resistant Staphylococcus aureus (S. aureus) infections, has shown significant efficacy in animal studies and is being rapidly developed for entry into the clinic.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory